(2R,3R,4S,5R,2'R,3'R,4'S,5'S)-2,2'-{TRANS-1,4-CICLOHEXANODIILBIS-[IMINO(2-{[2-(1-METIL-1H-IMIDAZOL-4-IL)ETIL]AMINO}-9H-PURIN-6,9-DIIL)]}BIS[5-(2-ETIL-2H-TETRAZOL-5-IL)TETRAHIDRO-3,4-FURANODIOL] COMO AGONISTA A2A
SE REFIERE A SALES Y SOLVATOS DE (2R,3R,4S,5R,2'R,3'R,4'S,5'S)-2,2'-{TRANS-1,4-CICLOHEXANODIILBIS-[IMINO(2-{[2-(1-METIL-1H-IMIDAZOL-4-IL)ETIL]AMINO}-9H-PURIN-6,9-DIIL)]}BIS[5-(2-ETIL-2H-TETRAZOL-5-IL)TETRAHIDRO-3,4-FURANODIOL] Y UN PROCEDIMIENTO DE PREPARACION. SE REFIERE TA...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Patent |
| Sprache: | spa |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | BLATCHER PHILIP COUSINS RICHARD PETER CHARLES EVANS DEREK NORMAN |
| description | SE REFIERE A SALES Y SOLVATOS DE (2R,3R,4S,5R,2'R,3'R,4'S,5'S)-2,2'-{TRANS-1,4-CICLOHEXANODIILBIS-[IMINO(2-{[2-(1-METIL-1H-IMIDAZOL-4-IL)ETIL]AMINO}-9H-PURIN-6,9-DIIL)]}BIS[5-(2-ETIL-2H-TETRAZOL-5-IL)TETRAHIDRO-3,4-FURANODIOL] Y UN PROCEDIMIENTO DE PREPARACION. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES AGONISTA POTENTE DEL RECEPTOR DE ADENOSINA A2A, UTIL EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS TALES COMO ASMA Y ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA
A compound of formula (I) and salts and solvates thereof are disclosed. Compounds of formula (I) are agonists of the adenosine A2A receptor and are believed to be of potential use in the treatment of inflammatory diseases such as asthma and chronic obstructive pulmonary disease. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_PE20060272A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>PE20060272A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_PE20060272A13</originalsourceid><addsrcrecordid>eNqNTktqwzAQ9aaL0vYO7so2aMAe2ylZqrZSDchSkBQoNSaEoq5KG0h3IafshSqbHiCLYXiP97tNfnO0rLascay1DLMI4jVZhJkrACMFZ2-5dlCxBjrqlJHilWvTE6lncjDSQNrkCOcRIa9gEJ4UVBIi3_M3o6ABUsXMTnyWXmAtYbuzpGHF1jDnFNMlRo0txJjFjhK8iLWzvZ3tC5LUWwN13LHZ2WWCUVPamcGk_MVocp6nHPl9cvNx-DyFh_9_lzxuhO8khOP3PpyOh_fwFX72W4FluSrxCXlVX6P5A_L5UA8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>(2R,3R,4S,5R,2'R,3'R,4'S,5'S)-2,2'-{TRANS-1,4-CICLOHEXANODIILBIS-[IMINO(2-{[2-(1-METIL-1H-IMIDAZOL-4-IL)ETIL]AMINO}-9H-PURIN-6,9-DIIL)]}BIS[5-(2-ETIL-2H-TETRAZOL-5-IL)TETRAHIDRO-3,4-FURANODIOL] COMO AGONISTA A2A</title><source>esp@cenet</source><creator>BLATCHER PHILIP ; COUSINS RICHARD PETER CHARLES ; EVANS DEREK NORMAN</creator><creatorcontrib>BLATCHER PHILIP ; COUSINS RICHARD PETER CHARLES ; EVANS DEREK NORMAN</creatorcontrib><description>SE REFIERE A SALES Y SOLVATOS DE (2R,3R,4S,5R,2'R,3'R,4'S,5'S)-2,2'-{TRANS-1,4-CICLOHEXANODIILBIS-[IMINO(2-{[2-(1-METIL-1H-IMIDAZOL-4-IL)ETIL]AMINO}-9H-PURIN-6,9-DIIL)]}BIS[5-(2-ETIL-2H-TETRAZOL-5-IL)TETRAHIDRO-3,4-FURANODIOL] Y UN PROCEDIMIENTO DE PREPARACION. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES AGONISTA POTENTE DEL RECEPTOR DE ADENOSINA A2A, UTIL EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS TALES COMO ASMA Y ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA
A compound of formula (I) and salts and solvates thereof are disclosed. Compounds of formula (I) are agonists of the adenosine A2A receptor and are believed to be of potential use in the treatment of inflammatory diseases such as asthma and chronic obstructive pulmonary disease.</description><language>spa</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2006</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20060522&DB=EPODOC&CC=PE&NR=20060272A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25563,76318</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20060522&DB=EPODOC&CC=PE&NR=20060272A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>BLATCHER PHILIP</creatorcontrib><creatorcontrib>COUSINS RICHARD PETER CHARLES</creatorcontrib><creatorcontrib>EVANS DEREK NORMAN</creatorcontrib><title>(2R,3R,4S,5R,2'R,3'R,4'S,5'S)-2,2'-{TRANS-1,4-CICLOHEXANODIILBIS-[IMINO(2-{[2-(1-METIL-1H-IMIDAZOL-4-IL)ETIL]AMINO}-9H-PURIN-6,9-DIIL)]}BIS[5-(2-ETIL-2H-TETRAZOL-5-IL)TETRAHIDRO-3,4-FURANODIOL] COMO AGONISTA A2A</title><description>SE REFIERE A SALES Y SOLVATOS DE (2R,3R,4S,5R,2'R,3'R,4'S,5'S)-2,2'-{TRANS-1,4-CICLOHEXANODIILBIS-[IMINO(2-{[2-(1-METIL-1H-IMIDAZOL-4-IL)ETIL]AMINO}-9H-PURIN-6,9-DIIL)]}BIS[5-(2-ETIL-2H-TETRAZOL-5-IL)TETRAHIDRO-3,4-FURANODIOL] Y UN PROCEDIMIENTO DE PREPARACION. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES AGONISTA POTENTE DEL RECEPTOR DE ADENOSINA A2A, UTIL EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS TALES COMO ASMA Y ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA
A compound of formula (I) and salts and solvates thereof are disclosed. Compounds of formula (I) are agonists of the adenosine A2A receptor and are believed to be of potential use in the treatment of inflammatory diseases such as asthma and chronic obstructive pulmonary disease.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2006</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNTktqwzAQ9aaL0vYO7so2aMAe2ylZqrZSDchSkBQoNSaEoq5KG0h3IafshSqbHiCLYXiP97tNfnO0rLascay1DLMI4jVZhJkrACMFZ2-5dlCxBjrqlJHilWvTE6lncjDSQNrkCOcRIa9gEJ4UVBIi3_M3o6ABUsXMTnyWXmAtYbuzpGHF1jDnFNMlRo0txJjFjhK8iLWzvZ3tC5LUWwN13LHZ2WWCUVPamcGk_MVocp6nHPl9cvNx-DyFh_9_lzxuhO8khOP3PpyOh_fwFX72W4FluSrxCXlVX6P5A_L5UA8</recordid><startdate>20060522</startdate><enddate>20060522</enddate><creator>BLATCHER PHILIP</creator><creator>COUSINS RICHARD PETER CHARLES</creator><creator>EVANS DEREK NORMAN</creator><scope>EVB</scope></search><sort><creationdate>20060522</creationdate><title>(2R,3R,4S,5R,2'R,3'R,4'S,5'S)-2,2'-{TRANS-1,4-CICLOHEXANODIILBIS-[IMINO(2-{[2-(1-METIL-1H-IMIDAZOL-4-IL)ETIL]AMINO}-9H-PURIN-6,9-DIIL)]}BIS[5-(2-ETIL-2H-TETRAZOL-5-IL)TETRAHIDRO-3,4-FURANODIOL] COMO AGONISTA A2A</title><author>BLATCHER PHILIP ; COUSINS RICHARD PETER CHARLES ; EVANS DEREK NORMAN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_PE20060272A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>spa</language><creationdate>2006</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>BLATCHER PHILIP</creatorcontrib><creatorcontrib>COUSINS RICHARD PETER CHARLES</creatorcontrib><creatorcontrib>EVANS DEREK NORMAN</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>BLATCHER PHILIP</au><au>COUSINS RICHARD PETER CHARLES</au><au>EVANS DEREK NORMAN</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>(2R,3R,4S,5R,2'R,3'R,4'S,5'S)-2,2'-{TRANS-1,4-CICLOHEXANODIILBIS-[IMINO(2-{[2-(1-METIL-1H-IMIDAZOL-4-IL)ETIL]AMINO}-9H-PURIN-6,9-DIIL)]}BIS[5-(2-ETIL-2H-TETRAZOL-5-IL)TETRAHIDRO-3,4-FURANODIOL] COMO AGONISTA A2A</title><date>2006-05-22</date><risdate>2006</risdate><abstract>SE REFIERE A SALES Y SOLVATOS DE (2R,3R,4S,5R,2'R,3'R,4'S,5'S)-2,2'-{TRANS-1,4-CICLOHEXANODIILBIS-[IMINO(2-{[2-(1-METIL-1H-IMIDAZOL-4-IL)ETIL]AMINO}-9H-PURIN-6,9-DIIL)]}BIS[5-(2-ETIL-2H-TETRAZOL-5-IL)TETRAHIDRO-3,4-FURANODIOL] Y UN PROCEDIMIENTO DE PREPARACION. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES AGONISTA POTENTE DEL RECEPTOR DE ADENOSINA A2A, UTIL EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS TALES COMO ASMA Y ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA
A compound of formula (I) and salts and solvates thereof are disclosed. Compounds of formula (I) are agonists of the adenosine A2A receptor and are believed to be of potential use in the treatment of inflammatory diseases such as asthma and chronic obstructive pulmonary disease.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | spa |
| recordid | cdi_epo_espacenet_PE20060272A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
| title | (2R,3R,4S,5R,2'R,3'R,4'S,5'S)-2,2'-{TRANS-1,4-CICLOHEXANODIILBIS-[IMINO(2-{[2-(1-METIL-1H-IMIDAZOL-4-IL)ETIL]AMINO}-9H-PURIN-6,9-DIIL)]}BIS[5-(2-ETIL-2H-TETRAZOL-5-IL)TETRAHIDRO-3,4-FURANODIOL] COMO AGONISTA A2A |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T10%3A49%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=BLATCHER%20PHILIP&rft.date=2006-05-22&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EPE20060272A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |